Completed PHASE3 INTERVENTIONAL 3-arm NCT00577993

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma

Sponsor: Genentech, Inc.

Conditions Lymphoma

Interventions Ara-C Bleomycin Cisplatin Cyclophosphamide Decadron Doxorubicin Etoposide Fludarabine Interferon Methyl-Prednisolone Novantrone Prednisone Procarbazine Rituximab Vincristine

Updated 9 times since 2017 Last updated: Oct 22, 2020 Started: Mar 16, 1998 Primary completion: Aug 24, 2017 Completion: Aug 24, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lymphoma, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2020 — Jan 2021 [monthly]

Completed PHASE3
Aug 2019 — Dec 2020 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Aug 2019 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States